SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK attention is driven mainly by speculative calls for a memecoin rebound alongside chatter about a possible Bonk.fun relaunch, growing holder counts and token burns; these developments are discussed as expectations rather than confirmed catalysts. Traders are largely bullish and adding to positions, while others complain that BONK has lagged or quickly surrendered gains.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, mostly sideways trading, with traders repeatedly discussing consolidation and whether it can break resistance or resume a decline. Some are accumulating and anticipating a rebound, while others call the token stagnant and question its utility and prospects.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Promising early data for Lillys investigational ovarian-cancer drug Sofe-M is drawing pipeline interest, while traders also weigh oncology updates against expectations for the quarterly report and continued obesity-drug growth. The mood is mixed: bullish comments about Lillys business and pipeline sit alongside concerns about the share-price pullback and valuation.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos is drawing attention after a prolonged selloff brought shares near their 52-week lows, despite contract announcements, a sizable backlog and bullish analyst coverage. Traders are split between buying the dip ahead of the Q3 earnings report and warning that rich valuation, insider selling and questions about converting demand into profits could keep pressure on the stock.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is drawing attention as traders watch its recovery toward recent highs, citing bullish technical signals and positioning in calls ahead of the upcoming earnings report. Bulls see momentum continuing, while skeptics point to repeated resistance and the stocks history of struggling to sustain breakouts.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentums AI data-center optics demandand CEO comments that key components are booked through early 2029underpin bullish discussion, alongside expectations for growth in optical networking. Traders are also debating valuation and capacity constraints as the stock and optical sector swing sharply, with some viewing the pullback as profit-taking and others warning that the crowded AI trade may be cooling.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys quarterly report and stronger-than-expected profit outlook are driving attention: traders point to premium subscriber growth, improving margins and faster ad growth as reasons for the sharp share gain, despite revenue and EPS misses. Others question the rally, citing rising expenses and weaker free cash flow.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention after a sharp pullback from a recent rebound, with traders debating whether buyers will defend support or the decline will deepen ahead of the companys earnings report. Bullish technical setups and call-option trades contrast with concerns about weak housing activity and interest-rate pressure; the discussion remains split.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention over reports that Aetnas 2027 Medicare Advantage star ratings have fallen, raising concern about lost quality bonuses and pressure on future margins. Traders debate whether the setback is already priced in, with some expecting a recovery while others point to the relative weakness versus insurers with improved ratings.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 report is driving discussion after a sharp book-value decline attributed mainly to wider Agency MBS spreads, intensifying concerns about the share-price drop and dividend coverage. Some traders remain cautious, while others point to managements confidence in liquidity and future returns, along with recent insider purchases, as reasons to stay invested or add shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe...

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be...

Why Mission Produce Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

Mission Produce rose 5.5% after beating Q3 earnings and sales estimates; several stocks rallied, while ServiceTitan and Evommune fell premarket.read more...

Why Is EVMN Stock Down 13% After-Hours?

Equity

Evommune said on Tuesday that its mid-stage trial involving its experimental eczema pill EVO756 failed a mid-stage study. 


Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial...

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update...

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective...

Evommune Becomes Oversold (EVMN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, July 7, 2026 Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous...

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) PR Newswire NEW YORK, June 30, 2026 Evommune's CEO and...

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>In June, EVO756 failed in a trial evaluating it for the treatment of chronic hives.&nbsp;</li><li>The company is now testing the drug as a possible migraine preventative.&nbsp;</li><li>Chief Executive Luis Peña said Evommune still wants to help eczema patients — through a different drug called EVO301.</li></ul><p>Shares of Evommune (EVMN) slumped 13% after-hours on Tuesday after the company said its experimental eczema pill failed a mid-stage study and will not move forward in that disease.</p><p>The Palo Alto biotech’s investors had been waiting on the readout as a second chance for EVO756, an oral drug that already missed its main goal in chronic hives earlier this year in June. The stock had gained 7% in the regular trading session.</p><h2 class="st-heading-2">Trial Misses, Program Dropped In Eczema</h2><p>The mid-stage study enrolled 121 adults with moderate-to-severe atopic dermatitis, a common form of eczema. Patients took one of several doses of EVO756 or a dummy pill for 12 weeks. The drug did not beat placebo on the study’s main measure of skin clearance, or on secondary goals, at any dose tested, the firm said.</p><p>Evommune said it will stop developing EVO756 for eczema. The medicine was generally well tolerated, with a safety picture in line with earlier studies.</p><p>“We are disappointed that this trial of EVO756 did not meet its primary endpoint, particularly given the need for new treatment options for patients suffering from AD,” Chief Medical Officer Eugene Bauer said.</p><p>The company will keep testing the same pill as a possible migraine preventive. That mid-stage study is already underway. Bauer said the safety results from the eczema trial support that next step.</p><h2 class="st-heading-2">A Different Eczema Bet</h2><p>Chief Executive Luis Peña said Evommune still wants to help eczema patients — through a different drug. EVO301, an injectable protein that showed a positive mid-stage signal earlier this year, is now the company’s lead eczema program. The company plans a larger mid-stage trial for mid-2027.</p><p>Peña said the company has cash to fund operations into 2029 and will keep working across chronic inflammatory diseases. “This trial did not deliver the outcome we and the AD community were hoping for,” he said.</p><p>In late June, after the company announced its hives trial had failed, Martin Shkreli, the hedge-fund manager turned drug-company executive known as “Pharma Bro,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2071592596959326381?s=20">posted</a> that he was going long EVMN on the drop and that it was a new position. His pitch was that the failed hives program was now out of the way and the remaining story was EVO301.</p><h2 class="st-heading-2">How Did EVMN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around EVMN stock jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/EVMN">EVMN stock</a> has lost 24% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bcrx-stock-posts-worst-day-in-over-6-months-after-phvs-trial-win-in-rare-swelling-disease/cZtEQyHRJy4">BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Evommune said on Tuesday that its mid-stage trial involving its experimental eczema pill EVO756 failed a mid-stage study. 

Evommune Inc

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$5.10
Prev Close	$5.21
Open	$5.18
Dividend Yield	0.00%
50-Day Moving Average	$9.62
Beta	1.16
Avg. Volume	805,292.89
PE Ratio	-1.80

52-Week High	$33.20
52-Week Low	$4.94
Market Capitalization	$185.09M
EPS (Annual)	-$2.18
Price to Book	0.67
Revenue Per Employee	$270,833.33

Feed

News

Sentiment

Fundamentals

Info

EVMN Fundamentals